BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9364821)

  • 1. Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients.
    Queiroz RH; Souza AM; Melchior E; Gouveia EG; Carvalho D
    Lepr Rev; 1997 Sep; 68(3):212-7. PubMed ID: 9364821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT.
    Queiroz RH; Melchior Júnior E; de Souza AM; Gouveia E; Barbosa JC; de Carvalho D
    Pharm Acta Helv; 1997 Sep; 72(4):209-13. PubMed ID: 9372643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and hematological side effects of clofazimine in leprosy patients.
    Costa Queiroz RH; de Souza AM; Sampaio SV; Melchior E
    Pharmacol Res; 2002 Aug; 46(2):191-4. PubMed ID: 12220960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapsone drug resistance in the MDT era.
    Roche PW; Neupane KD; Failbus SS; Butlin CR
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
    [No Abstract]   [Full Text] [Related]  

  • 5. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minocycline is effective and cosmetically preferred to clofazimine by leprosy patients in New York.
    Levis WR; Spencer TI; Ladizinski B
    J Drugs Dermatol; 2010 Aug; 9(8):906. PubMed ID: 20684139
    [No Abstract]   [Full Text] [Related]  

  • 7. Aplastic anaemia associated with multidrug therapy (dapsone, rifampicin and clofazimine) in a patient with lepromatous leprosy.
    Goulart IM; Reis AC; De Rezende TM; Borges AS; Ferreira MS; Nishioka SA
    Lepr Rev; 2005 Jun; 76(2):167-9. PubMed ID: 16038251
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
    Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
    Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic and haematological adverse reactions associated with the use of multidrug therapy in leprosy--a five year retrospective study.
    Kaluarachchi SI; Fernandopulle BM; Gunawardane BP
    Indian J Lepr; 2001; 73(2):121-9. PubMed ID: 11579648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug therapy regimen for leprosy.
    Firooz A
    J Am Acad Dermatol; 2006 Dec; 55(6):1115; author reply 1115. PubMed ID: 17110233
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
    Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
    An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antileprosy drugs, pregnancy and fetal outcome.
    Bhargava P; Kuldeep CM; Mathur NK
    Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):457-8. PubMed ID: 9030117
    [No Abstract]   [Full Text] [Related]  

  • 13. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
    Deps P; Guerra P; Nasser S; Simon M
    Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal hypersensitivity vasculitis associated with dapsone.
    Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Rabel-Filho OC; Martini-Filho D; Fontes CJ
    Am J Kidney Dis; 2005 Oct; 46(4):e51-3. PubMed ID: 16183407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.
    Lim JT; Tan T
    Lepr Rev; 1993 Jun; 64(2):136-42. PubMed ID: 8341116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
    Groenen G; Janssens L; Kayembe T; Nollet E; Coussens L; Pattyn SR
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):236-44. PubMed ID: 3722962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy in leprosy.
    Gatti JC
    Lepr Rev; 1975 Jun; 46(2 Suppl):155-60. PubMed ID: 1100955
    [No Abstract]   [Full Text] [Related]  

  • 19. Dapsone-induced haemolytic anaemia, hepatitis and agranulocytosis in a leprosy patient with normal glucose-6-phosphate-dehydrogenase activity.
    Ranawaka RR; Mendis S; Weerakoon HS
    Lepr Rev; 2008 Dec; 79(4):436-40. PubMed ID: 19274991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibacterial chemotherapy in leprosy: principles, objectives and recommendations].
    Sansarricq H
    Acta Leprol; 1986; 4(3):355-62. PubMed ID: 3551474
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.